IL137510A0 - Compositions comprising viruses and methods for concentrating virus preparations - Google Patents

Compositions comprising viruses and methods for concentrating virus preparations

Info

Publication number
IL137510A0
IL137510A0 IL13751099A IL13751099A IL137510A0 IL 137510 A0 IL137510 A0 IL 137510A0 IL 13751099 A IL13751099 A IL 13751099A IL 13751099 A IL13751099 A IL 13751099A IL 137510 A0 IL137510 A0 IL 137510A0
Authority
IL
Israel
Prior art keywords
viruses
compositions
methods
virus preparations
concentrating virus
Prior art date
Application number
IL13751099A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL137510A0 publication Critical patent/IL137510A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
IL13751099A 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations IL137510A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (1)

Publication Number Publication Date
IL137510A0 true IL137510A0 (en) 2001-07-24

Family

ID=26698472

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13751099A IL137510A0 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations
IL137510A IL137510A (en) 1998-02-17 2000-07-25 Vaccines for maintaining the stability of adenoviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137510A IL137510A (en) 1998-02-17 2000-07-25 Vaccines for maintaining the stability of adenoviruses

Country Status (25)

Country Link
EP (4) EP1741777B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100862169B1 (de)
CN (2) CN100374551C (de)
AR (3) AR020054A1 (de)
AT (3) ATE478945T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2320419C (de)
CO (1) CO4820440A1 (de)
DE (3) DE69936948T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2290613T3 (de)
HK (3) HK1073481A1 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968284B1 (de) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ATE421337T1 (de) * 1998-11-16 2009-02-15 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001066137A1 (en) * 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A1 (en) * 2000-12-12 2002-06-24 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
CA2469721A1 (en) * 2002-01-18 2003-07-31 Schering Aktiengesellschaft Stabilized formulations of adenovirus
DK1780269T3 (da) 2004-02-23 2009-10-12 Crucell Holland Bv Virusrensningsmetoder
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
ES2377356T3 (es) * 2006-04-20 2012-03-26 Wyeth Llc Procedimiento de purificación para el aislamiento del virus purificado de la estomatitis vesicular de un cultivo celular
KR101504392B1 (ko) 2008-11-03 2015-03-19 크루셀 홀란드 비.브이. 아데노바이러스 벡터의 제조방법
WO2010129021A1 (en) 2009-05-02 2010-11-11 Genzyme Corporation Gene therapy for neurodegenerative disorders
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
KR102151890B1 (ko) * 2011-04-29 2020-09-03 온콜리틱스 바이오테크 인코포레이티드 겔 침투 크로마토그래피를 이용한 바이러스의 정제방법
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
CN105188745B (zh) 2013-04-25 2019-10-18 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3010931B1 (de) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
EP3149022A4 (de) * 2014-05-28 2018-01-10 Agency for Science, Technology and Research Virusreduktionsverfahren
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
JP2019523644A (ja) 2016-05-30 2019-08-29 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された融合前ｒｓｖ ｆタンパク質
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
US20220267796A1 (en) * 2019-06-28 2022-08-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
KR20220134622A (ko) 2020-01-31 2022-10-05 베쓰 이스라엘 디코니스 메디칼 센터 인크 코로나바이러스 감염 예방 및 치료용 조성물 및 방법 - sars-cov-2 백신
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN115989321A (zh) * 2021-08-17 2023-04-18 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
NO20004104L (no) 2000-10-17
DE69933433T2 (de) 2007-08-23
PT1054955E (pt) 2007-01-31
JP2006166925A (ja) 2006-06-29
WO1999041416A2 (en) 1999-08-19
EP1526174B1 (de) 2007-08-22
CO4820440A1 (es) 1999-07-28
DE69936948D1 (de) 2007-10-04
KR100991683B1 (ko) 2010-11-04
CN1297478A (zh) 2001-05-30
PE20000265A1 (es) 2000-04-25
CN101164623B (zh) 2012-11-14
SK11842000A3 (sk) 2001-05-10
HK1073481A1 (en) 2005-10-07
TWI232107B (en) 2005-05-11
NO20004104D0 (no) 2000-08-16
ATE478945T1 (de) 2010-09-15
ID28298A (id) 2001-05-10
IL137510A (en) 2012-10-31
KR100912362B1 (ko) 2009-08-19
CN101164623A (zh) 2008-04-23
JP4358434B2 (ja) 2009-11-04
AR063314A2 (es) 2009-01-21
EP1054955B1 (de) 2006-10-04
BR9908015A (pt) 2001-04-24
EP1526173A3 (de) 2005-08-10
AR063315A2 (es) 2009-01-21
DE69942708D1 (de) 2010-10-07
CA2723040A1 (en) 1999-08-19
KR20010072547A (ko) 2001-07-31
KR100862169B1 (ko) 2008-10-09
EP1054955A2 (de) 2000-11-29
EP1741777A1 (de) 2007-01-10
EP1526173A2 (de) 2005-04-27
HUP0100670A3 (en) 2003-10-28
HUP0100670A2 (hu) 2001-06-28
AU2653899A (en) 1999-08-30
ES2290613T3 (es) 2008-02-16
WO1999041416A3 (en) 1999-11-18
HU226015B1 (en) 2008-02-28
AR020054A1 (es) 2002-04-10
JP2010213727A (ja) 2010-09-30
ATE371020T1 (de) 2007-09-15
ATE341614T1 (de) 2006-10-15
KR101018992B1 (ko) 2011-03-07
KR20080065615A (ko) 2008-07-14
EP1526174A3 (de) 2005-08-31
MY141641A (en) 2010-05-31
EP1741777B1 (de) 2010-08-25
DK1054955T3 (da) 2007-01-15
PL342847A1 (en) 2001-07-16
EP1526173B1 (de) 2012-11-21
CA2320419C (en) 2011-02-08
KR20090038927A (ko) 2009-04-21
JP2002503484A (ja) 2002-02-05
EP1526174A2 (de) 2005-04-27
DE69933433D1 (de) 2006-11-16
KR20080065614A (ko) 2008-07-14
PL197747B1 (pl) 2008-04-30
CA2320419A1 (en) 1999-08-19
ES2272053T3 (es) 2007-04-16
DE69936948T2 (de) 2008-05-15
CN100374551C (zh) 2008-03-12
AU757976B2 (en) 2003-03-13
KR20090127947A (ko) 2009-12-14
HK1097413A1 (en) 2007-06-22
KR100918187B1 (ko) 2009-09-22
HK1028416A1 (en) 2001-02-16

Similar Documents

Publication Publication Date Title
HK1097413A1 (en) Compositions comprising viruses and methods for concentrating virus preparations
EP1292603B8 (de) Verfahren und zusammensetzungen zur behandlung des hepatitis c virus
GB2337755B (en) Virus vaccine
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
HUP0103908A3 (en) Novel infulenza virus vaccine composition
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CZ20011341A3 (cs) Pomocné přípravky a vakciny
HUP0104548A3 (en) Hepatitis c inhibitor peptides, process for their preparation, pharmaceutical compositions conprising thereof and their use
EP0939835A4 (de) Zusammensetzungen und verfahren zur behandlung von viralen infektionen
AU6512299A (en) Gemini virus vectors for gene expression in plants
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
EP1052988A4 (de) Methoden und zusammenstellungen zur inaktivierung von viren
AU3714499A (en) Hepatitis c virus mimotopes
AU7261898A (en) Methods for viral inactivation and compositions for use in same
HK1046911A1 (zh) 經穩定的病毒外膜蛋白質及其使用
AU4132096A (en) Compositions and methods for interfering with hepatitis b virus infection
AU8382198A (en) Methods for inactivating enveloped rna virus particles and compositions for use therewith
EP1068362A4 (de) Hepatitis c virus ns5b zusammensetzungen und verfahren zu deren verwendung
GB9809666D0 (en) Modified viruses
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.
GB2351904B (en) Herbal composition and use of the composition for treating viral infection of the liver
GB9925432D0 (en) Virus preparation
GB9707221D0 (en) Hepatitis B virus mutations
AU2002302069A1 (en) Virus preparations and methods
GB9908224D0 (en) Virus preparations and methods